{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:38:13Z","timestamp":1790516293607,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.ijantimicag.2004.11.006","type":"journal-article","created":{"date-parts":[[2005,2,11]],"date-time":"2005-02-11T14:16:45Z","timestamp":1108131405000},"page":"185-192","source":"Crossref","is-referenced-by-count":52,"title":["Tigecycline: clinical evidence and formulary positioning"],"prefix":"10.1016","volume":"25","author":[{"given":"Dilip","family":"Nathwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2004.11.006_bib1","unstructured":"Monitoring hospital-acquired infections to promote patient safety, United States, 1990\u20131999. MMWR Morb Mortal Wkly Rep 2000; 49:149\u201353."},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib2","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1136\/bmj.325.7377.1390","article-title":"Mortality from methicillin resistant Staphylococcus aureus in England and Wales: analysis of death certificates","volume":"325","author":"Crowcroft","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib3","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1086\/375081","article-title":"The impact of antimicrobial resistance on health and economic outcomes","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMp048093","article-title":"The antibiotic pipeline\u2014challenges, costs, and values","volume":"351","author":"Wenzel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1086\/380457","article-title":"Antimicrobial resistance trends and outbreak frequency in United States hospitals","volume":"38","author":"Diekema","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1345\/aph.1C437","article-title":"Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program","volume":"37","author":"Mutnick","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/421471","article-title":"Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA","volume":"190","author":"Meka","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s15010-004-3009-0","article-title":"Linezolid-resistant Enterococcus faecium and Enterococcus faecalis isolated from a septic patient: report of first isolates in Germany","volume":"32","author":"Halle","year":"2004","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib9","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.2165\/00003495-200363200-00001","article-title":"Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time","volume":"63","author":"Kollef","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1367-5931(00)00106-X","article-title":"New approaches in the treatment of bacterial infections","volume":"4","author":"Bush","year":"2000","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1471-4892(01)00081-9","article-title":"Glycylcyclines: third-generation tetracycline antibiotics","volume":"1","author":"Chopra","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003495-200464010-00005","article-title":"The glycylcyclines: a comparative review with the tetracyclines","volume":"64","author":"Zhanel","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1592\/phco.24.1.58.34808","article-title":"Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria","volume":"24","author":"Guay","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib15","unstructured":"Wyeth Pharmaceuticals. Data on File."},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib16","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A5","author":"NCCLS","year":"2003"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib17","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1128\/AAC.38.7.1658","article-title":"Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines","volume":"38","author":"Rasmussen","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib18","doi-asserted-by":"crossref","first-page":"219S","DOI":"10.1592\/phco.20.14.219S.35046","article-title":"Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent","volume":"20","author":"Projan","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib19","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1128\/AAC.40.9.2226","article-title":"Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection","volume":"40","author":"Bergeron","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib20","series-title":"Progr Abstr 34th Intersci Conf Antimicrob Agents Chemother, Orlando, October","article-title":"The potential for the emergence of resistance to the glycylcyclines among tetracycline resistant staphylococci","author":"Projan","year":"1994"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/AAC.39.1.247","article-title":"A novel glycylcycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline\/H+ antiporter","volume":"39","author":"Someya","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib22","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1128\/AAC.44.11.3022-3027.2000","article-title":"Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis","volume":"44","author":"Murphy","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib23","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/AAC.44.4.943-949.2000","article-title":"In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria","volume":"44","author":"van Ogtrop","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib24","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1128\/AAC.44.4.1085-1088.2000","article-title":"Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci","volume":"44","author":"Hoellman","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib25","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1086\/381972","article-title":"Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections","volume":"38","author":"Pankey","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1542\/peds.58.3.378","article-title":"Prolonged pneumococcal meningitis due to an organism with increased resistance to penicillin","volume":"58","author":"Paredes","year":"1976","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0002-9343(76)90758-0","article-title":"Clindamycin therapy of Staphylococcus aureus endocarditis. Clinical relapse and development of resistance to clindamycin, lincomycin and erythromycin","volume":"60","author":"Watanakunakorn","year":"1976","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib28","first-page":"87","article-title":"Antimicrobial treatment of osteomyelitis","author":"Mader","year":"1993","journal-title":"Clin Orthop"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib29","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/319986","article-title":"Successful treatment of vancomycin-resistant enterococcus endocarditis with oral linezolid","volume":"32","author":"Babcock","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib30","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/dkf215","article-title":"The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin","volume":"50","author":"Moise","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/AAC.44.4.943-949.2000","article-title":"In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria","volume":"44","author":"van Ogtrop","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib32","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0149-2918(04)90070-7","article-title":"A multicenter, randomized, open-label safety and efficacy study of tigecycline dosages for complicated skin and skin structure infections in hospitalized patients","volume":"26","author":"Postier","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2004.11.006_bib33","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1086\/381971","article-title":"Hospital-acquired infective endocarditis: should the definition be broadened?","volume":"38","author":"Ben-Ami","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2004.11.006_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000048564","article-title":"The management of skin and soft tissue infections: outpatient parenteral antibiotic therapy in the United Kingdom","volume":"47","author":"Nathwani","year":"2001","journal-title":"Chemotherapy"},{"issue":"Suppl A","key":"10.1016\/j.ijantimicag.2004.11.006_bib35","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0195-6701(01)90032-5","article-title":"Economic impact and formulary positioning of linezolid: a new anti-Gram-positive antimicrobial","volume":"49","author":"Nathwani","year":"2001","journal-title":"J Hosp Infect"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2004.11.006_bib36","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1086\/383271","article-title":"Medical treatment of diabetic foot infections","volume":"39","author":"Lipsky","year":"2004","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857904004224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857904004224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T04:47:07Z","timestamp":1683002827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857904004224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0924857904004224"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2004.11.006","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}